Unknown

Dataset Information

0

Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells.


ABSTRACT: Tamoxifen (TAM) is widely used as an adjuvant therapy for women with breast cancer (BC). However, TAM possesses partial oestrogenic activity in the uterus and its use has been associated with an increased incidence of endometrial carcinoma (EC). The molecular mechanism for these observations is not well understood. Herein, we demonstrated that forced expression of Trefoil factor 3 (TFF3), in oestrogen receptor-positive (ER+) EC cells significantly increased cell cycle progression, cell survival, anchorage-independent growth, invasiveness and tumour growth in xenograft models. Clinically, elevated TFF3 protein expression was observed in EC compared with normal endometrial tissue, and its increased expression in EC was significantly associated with myometrial invasion. TAM exposure increased expression of TFF3 in ER+ EC cells and its elevated expression resulted in increased oncogenicity and invasiveness. TAM-stimulated expression of TFF3 in EC cells was associated with hypomethylation of the TFF3 promoter sequence and c-JUN/SP1-dependent transcriptional activation. In addition, small interfering (si) RNA-mediated depletion or polyclonal antibody inhibition of TFF3 significantly abrogated oncogenicity and invasiveness in EC cells consequent to TAM induction or forced expression of TFF3. Hence, TAM-stimulated upregulation of TFF3 in EC cells was critical in promoting EC progression associated with TAM treatment. Importantly, inhibition of TFF3 function might be an attractive molecular modality to abrogate the stimulatory effects of TAM on endometrial tissue and to limit the progression of EC.

SUBMITTER: Pandey V 

PROVIDER: S-EPMC5652779 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells.

Pandey Vijay V   Zhang Min M   Chong Qing-Yun QY   You Mingliang M   Raquib Ainiah Rushdiana AR   Pandey Amit K AK   Liu Dong-Xu DX   Liu Liang L   Ma Lan L   Jha Sudhakar S   Wu Zheng-Sheng ZS   Zhu Tao T   Lobie Peter E PE  

Oncotarget 20170824 44


Tamoxifen (TAM) is widely used as an adjuvant therapy for women with breast cancer (BC). However, TAM possesses partial oestrogenic activity in the uterus and its use has been associated with an increased incidence of endometrial carcinoma (EC). The molecular mechanism for these observations is not well understood. Herein, we demonstrated that forced expression of <i>Trefoil factor 3</i> (<i>TFF3)</i>, in oestrogen receptor-positive (ER+) EC cells significantly increased cell cycle progression,  ...[more]

Similar Datasets

| S-EPMC5479276 | biostudies-literature
| S-EPMC5650333 | biostudies-literature
2024-05-24 | GSE211456 | GEO
| S-EPMC5503616 | biostudies-literature
2024-05-24 | GSE240467 | GEO
| S-EPMC2488240 | biostudies-literature
| S-EPMC9876575 | biostudies-literature
| S-EPMC3378515 | biostudies-literature
| S-EPMC5220316 | biostudies-literature
2024-05-24 | GSE211455 | GEO